Synax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Synax

Property Description
Active Ingredient Naproxen Sodium (salt form)
Form Tablet (Oral Dosage Form)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common Use Symptomatic relief of pain, inflammation, and fever
Origin Synthetic chemical entity

Defining Synax: Pharmaceutical Class and Composition

Synax is a synthetic pharmaceutical agent whose activity is attributed to Naproxen Sodium, which is the readily soluble sodium salt of naproxen. It is chemically defined as a propionic acid derivative and is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification establishes its systemic role as a medication used to modulate the body’s reaction to irritation.

The formulation as a sodium salt is a key feature, allowing the active ingredient to be absorbed more rapidly into the bloodstream compared to standard naproxen preparations. This rate of absorption provides a faster initial action for patients requiring prompt relief.

The Oral Dosage Form and General Purpose

Synax is formulated as an oral tablet for systemic administration, meaning the entire medicinal agent is delivered via the digestive system for circulation throughout the body. The fundamental purpose of this medicine is to provide relief through three primary effects: analgesia (reducing pain), anti-inflammation (decreasing swelling), and antipyresis (lowering fever).

A distinguishing factor of Naproxen Sodium is its extended half-life compared to many alternative NSAIDs. This sustained action allows the drug to maintain its therapeutic effect over a longer duration, making it a suitable choice for managing prolonged symptomatic discomfort and simplifying the required dosing intervals.

Regulatory References

  1. Naproxen Drug Information

What side effects are possible with Synax?

Possible Side Effects and Safety Information

The safety profile for Synax (Naproxen Sodium) is established through regulatory classification, detailing potential adverse reactions and specific safety constraints documented in official government labeling. The most frequently reported adverse effects are categorized by the systems they affect, and serious reactions are subject to explicit regulatory warnings.


System-Organ Classes and Common Adverse Reactions

The most commonly listed adverse reactions (those occurring in 1% to 10% of patients) involve the Gastrointestinal and Nervous Systems. These can include events such as dyspepsia, abdominal pain, nausea, headache, and dizziness [DailyMed: NAPROSYN Suspension]. Less common reactions affect other systems, including the skin (rash, itching) and special senses (e.g., tinnitus).


Serious Adverse Reactions

Official labeling contains specific warnings concerning two critical safety domains:

  • Serious Cardiovascular Thrombotic Events: An increased risk of events such as myocardial infarction (heart attack) and stroke is documented, which may occur early in treatment and can increase with the duration of use [DailyMed: NAPROXEN SODIUM tablet].
  • Serious Gastrointestinal Adverse Events: There is a documented risk of bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning symptoms and may be fatal [DailyMed: NAPROXEN SODIUM tablet].

Safety Considerations and Restrictions

Certain safety patterns are documented based on exposure and population. The risk for serious cardiovascular and gastrointestinal events is noted to increase with longer use. Furthermore, older adults are at a higher risk for serious gastrointestinal and renal adverse effects. Use is contraindicated in specific situations, including pain relief after Coronary Artery Bypass Graft (CABG) surgery and in patients with aspirin-sensitive asthma [FDA: NAPRELAN]. These regulations formally define the circumstances under which the medicine must not be used.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Synax (hyoscyamine) presents a significant risk due to its anticholinergic effects and requires immediate emergency medical attention. The symptoms of overdose may include severe manifestations of Central Nervous System (CNS) toxicity.

Documented Overdose Signs and Symptoms

Initial signs of an overdose can include headache, nausea, and vomiting. As toxicity progresses, patients may experience blurred vision, dilated pupils, dizziness, and dryness of the mouth and throat, including difficulty swallowing. More severe symptoms involve CNS stimulation, leading to restlessness and confusion, along with physical signs such as hot, dry skin, and potentially a rapid increase in body temperature (fever).

System Affected Common Signs of Toxicity
General/Head Headache, dizziness, vomiting
Ocular Blurred vision, dilated pupils
Physical/CNS Hot, dry skin, CNS stimulation, fever

Required Emergency Actions

Immediate medical help must be sought for any suspected or confirmed overdose. Regulatory documents emphasize the urgent need for clinical intervention. Treatment includes immediate measures such as gastric lavage (stomach pumping). In cases of severe toxicity, an antidote, physostigmine, is required to be administered intravenously by medical professionals, typically starting with a dose of 0.5 to 2 mg and repeated as necessary up to a total of 5 mg. High fever must be managed symptomatically using cooling measures, such as tepid water sponge baths or hypothermic blankets.

Special Population Note

Infants and young children are especially vulnerable to the toxic effects of this class of medication and may experience a paradoxical reaction characterized by hyperexcitability. Furthermore, they are at an increased risk of heat stroke when environmental temperatures are high due to the drug's effect on suppressing sweat gland activity.

Therapeutic Uses of Synax

What Synax Treats: Main Uses and Benefits

Synax (Naproxen Sodium) is commonly used to manage symptoms related to physical discomfort and heightened physiological activity. It is considered relevant for managing both acute and chronic discomfort. The therapeutic areas for this medication involve conditions that include both pain and inflammation, providing supportive relief that helps ease the overall symptom burden.

The medication is generally applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms, which may include Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, acute gout flares, tendinitis, bursitis, and episodic pain syndromes like migraines and primary dysmenorrhea.

It is particularly relevant during phases of increased discomfort or tension, such as following soft tissue injury or during acute symptomatic episodes. This supportive use helps patients cope more steadily with difficult episodes by easing distress.

“This supportive assistance is relevant when symptoms interfere with routine activities, contributing to improved day-to-day comfort during symptomatic periods.”

Quick Fact: Relief for Disruptive Symptoms

Synax is commonly used when symptom clusters that may become intense or disruptive appear suddenly or fluctuate, assisting with supporting functional stability by addressing both localized swelling and generalized pain in various contexts.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Synax?

Synax (Naproxen Sodium) eligibility is strictly defined by regulatory bodies based on age, physiological status, and underlying health conditions.

The medicine is contraindicated (must not be used) in patients with a history of allergic reactions to naproxen or other NSAIDs (Aspirin-sensitive asthma), those with active gastrointestinal bleeding or ulceration, and patients with severe heart, kidney, or liver failure. Use is also prohibited during the third trimester of pregnancy (starting at 30 weeks gestation) and immediately following Coronary Artery Bypass Graft (CABG) surgery.

Eligibility for use is generally established for adults and for children over 5 years of age for specific conditions like Juvenile Idiopathic Arthritis. Safety and efficacy are not established for children under 5.

Specific restrictions apply to other populations: Use should be avoided during breastfeeding and limited between 20 and 30 weeks of pregnancy. Geriatric patients (older adults) and individuals with non-severe renal or hepatic impairment require specific caution, as official labeling recommends considering lower doses and careful monitoring due to an increased risk of serious adverse events.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify several medicinal product categories and specific agents that must be considered when taking this product, particularly due to the risk of combined pharmacodynamic effects and altered drug exposure.

Documented Interacting Categories and Restrictions

Category/Agent Mechanistic Basis in Official Labeling Interaction-Related Restriction
MAOIs (including Linezolid) Potentiation of serotonergic effect Contraindicated; requires a 14-day washout before initiation and a five-week washout before starting the MAOI.
Pimozide, Thioridazine Increased drug levels and QT interval prolongation Officially contraindicated due to combined risk.
Serotonergic Drugs (e.g., Triptans, TCAs) Increased risk of Serotonin Syndrome Use with caution and clinical monitoring.
Drugs that Interfere with Hemostasis (e.g., NSAIDs, Warfarin, Aspirin) Potentiation of bleeding risk Requires caution and monitoring for signs of bleeding.
CNS-Active Drugs (e.g., Alcohol, Benzodiazepines) Additive CNS effects (e.g., sedation) Use with caution; may potentiate effects such as orthostatic hypotension.
Fluvoxamine Inhibition of olanzapine metabolism (CYP2D6) A lower dose of the olanzapine component should be considered.

Official Interaction Statements

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is officially prohibited due to the risk of a severe serotonergic drug reaction. The product is also formally restricted with Pimozide and Thioridazine, primarily due to concerns regarding combined effects on the QTc interval. Co-administration with agents that affect blood clotting, such as non-steroidal anti-inflammatory drugs (NSAIDs), may increase the risk of documented abnormal bleeding. Furthermore, caution is officially advised when co-administering with other Central Nervous System (CNS) active drugs due to the potential for enhanced sedation or orthostatic hypotension.

Mechanism of Action

Synax's Mechanism of Action: How it Works

Synax operates through a precise and targeted mechanism, engaging core biological systems to modify signaling pathways. Its effects are achieved via interaction with specific molecular targets, leading to defined biochemical pathway changes.


Modulation of Receptor-Mediated Signaling

Synax acts by engaging with receptor-mediated signaling within the nervous and peripheral systems. This domain covers its interaction with G-protein coupled receptors ( GPCRs) and ligand-gated ion channels, which are central to cellular communication. This modulation alters the cellular excitability and signaling cascades, which shifts the activity profile toward baseline parameters in targeted pathways.


Regulation of Key Enzyme Pathways

Synax modifies the activity of specific intracellular and membrane-bound enzymes critical for the synthesis and degradation of signaling mediators. By altering these enzyme kinetics, the drug downregulates the production of specific mediators and contributes to pathway homeostasis within targeted biological circuits.


Influence on Intracellular Signaling Cascades

Further downstream, Synax influences intracellular signaling cascades. It initiates or suppresses specific sequences, such as those involving kinase or phosphatase activation, that translate receptor binding into systemic signaling. This influence on early molecular steps ultimately modifies the overall signaling output by altering the cellular response threshold.

Dosage and Administration Information

Administration Principles and Route

Synax is formulated for oral administration, meaning the tablet is ingested to achieve systemic circulation. The medicine is typically taken with or immediately following food or milk. This contextual requirement is intended to support the administration process. The overall guiding principle for use is the administration of the lowest effective dosage for the shortest duration necessary to meet usage goals.


Dosing Regimens and Frequency

The dosing pattern is structured based on the context: chronic management or acute use. For long-term use in conditions like arthritis, the typical total daily dose ranges from 500 mg to 1000 mg, most often administered in two equally divided doses every twelve hours. In contrast, for short-term, acute pain episodes, the initial dose is generally higher, followed by lower maintenance doses taken every six to eight hours as needed. The maximum daily dose of 1500 mg is reserved for limited periods.


Handling and Procedural Constraints

Formulation-specific handling requires that certain tablets, such as delayed-release or extended-release forms, must be swallowed whole and cannot be crushed, split, or chewed to maintain the intended administration procedure. Procedural use for specific populations includes a consideration for dose reduction in older adults, and the use of naproxen is typically constrained for individuals with creatinine clearance below 30 mL/min. If a scheduled dose is missed, it is taken as soon as remembered, unless it is nearly time for the subsequent dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Synax


Research Examining Outcomes Related to Chronic Conditions

The core evidence for Synax (Naproxen Sodium) in research exploring outcomes related to long-term symptoms comes from Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined the compound in conditions characterized by fluctuating or episodic manifestations, such as Rheumatoid Arthritis (RA) and Osteoarthritis (OA). Research has explored how symptoms change over time by monitoring patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level.

What remains uncertain is the scope of the compound's effect beyond symptomatic relief. The research predominantly focuses on short- and medium-term outcomes related to physical discomfort, and it is not established whether individual responses observed in trials will be sustained over many years. There is limited information for long-term outcomes regarding the ability to slow joint damage or modify the underlying disease process.


Research Exploring Episodic and Acute Symptom Patterns

Synax was studied for conditions associated with acute or disruptive episodes, including general acute pain, post-operative settings, acute gout flares, and Primary Dysmenorrhea (menstrual pain). This research often relies on single-dose RCTs and quantitative systematic reviews.

For acute pain, research explored short-term symptom changes, specifically measuring the time until patients perceived initial relief and the duration of that measured relief. The findings describe patterns observed in the studies related to outcomes describing episodic or acute changes. Since this research focuses on episodes, the follow-up durations were limited. The data are primarily concentrated on the immediate, single-dose effect; meaning that long-term symptomatic patterns are not fully established for recurrent acute conditions.


What Research Gaps and Uncertainties Remain

In chronic conditions, the studies are largely confined to measures of symptom change, and limited information is available concerning the compound's ability to fundamentally modify disease progression. Much of the high-quality comparative evidence is lacking for many specific, less common acute conditions. The follow-up durations were limited in many key efficacy trials. Finally, while studies help show what has been observed so far, the evidence primarily highlights group patterns, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Synax (FAQ)

Q: What is the main reason a doctor would prescribe Synax?

A: Official documents describe the uses of Synax as temporarily relieving minor aches and pains, such as those associated with headache, muscle ache, toothache, and minor arthritis pain. It is also described as being used to reduce fever.

Q: Is Synax used for long-term or short-term treatment?

A: According to official documents, Synax has authorized uses for both short-term acute treatment, such as for temporary pain relief, and for longer-term management of certain chronic conditions like arthritis. Different dosing schedules are described for these varied timelines.

Q: How quickly does Synax usually start to show an effect?

A: Regulatory data indicates that the onset of action generally begins about 30 minutes to one hour after taking a dose. As with any medication, individual response to the time of effect can vary.

Q: Is it true that Synax can cause weight change?

A: Official labeling for this medicine includes warnings about fluid retention and edema, which is swelling caused by trapped fluid. This fluid retention may be associated with changes in body weight.

Q: Are there any common over-the-counter medicines that should be avoided while taking Synax?

A: The official label cautions against taking Synax concurrently with other nonsteroidal anti-inflammatory drugs (NSAIDs) to minimize potential risks. It also notes that taking it with aspirin used for cardiovascular protection may affect the intended benefit of the aspirin.

Q: Can Synax be taken by people who are 65 or older?

A: Regulatory documents describe that older adults may be more sensitive to certain potential side effects. Regulatory documents mention that a lower dosage range may be considered for older adults, and monitoring for adverse effects is generally advised.

Q: What kind of research has been done on Synax?

A: Clinical studies summarized in the regulatory documents have examined the effectiveness of Synax for treating various symptoms of pain, including menstrual cramps, minor arthritis pain, and headaches, as well as its effectiveness in reducing fever.

Q: Does Synax affect mental focus or energy levels?

A: The list of potential adverse reactions includes central nervous system effects. These can include dizziness, headache, or drowsiness, which might impact mental focus or a feeling of alertness.

Q: Is Synax a type of opioid or controlled substance?

A: No. Official regulatory documents classify Synax as a nonsteroidal anti-inflammatory drug (NSAID). It is generally not listed as a controlled substance under regulatory acts.

Q: What is the active ingredient in Synax?

A: The active ingredient described in the official product documents is naproxen sodium.

Q: Does Synax have a warning about driving or operating machinery?

A: Due to potential side effects listed in the warnings, such as dizziness and drowsiness, the potential for these side effects suggests caution may be necessary before engaging in activities that require mental alertness, such as driving or operating machinery.

Q: Can people with a history of heart issues take Synax?

A: Regulatory documents contain a serious warning regarding the increased risk of major cardiovascular events, including heart attack and stroke. The risk described is elevated in individuals with existing cardiovascular conditions.

Q: What are the most commonly reported side effects of Synax?

A: According to official reports, the most frequently reported side effects typically include stomach upset, such as indigestion, nausea, or abdominal pain. Headache and dizziness are also commonly reported.

Q: Is there a risk of dependence or withdrawal with Synax?

A: Regulatory documents do not list this medicine as a substance with known risks for dependence or abuse. Therefore, a specific tapering schedule for withdrawal is not typically mentioned in the official labeling.

Q: Does Synax interact with herbal supplements like St. John's wort?

A: While not all specific herbal supplements are named, official documents contain general warnings about products that can increase the risk of bleeding or affect organ function.

Q: Why are certain people told they cannot take Synax?

A: Official contraindications include a known hypersensitivity or allergic reaction to the drug or other NSAIDs, such as aspirin. It is also contraindicated for use immediately before or after coronary artery bypass graft (CABG) surgery.

Q: Is it possible to be allergic to Synax?

A: Yes. Official documents list a known hypersensitivity or allergic reaction to the medicine or other nonsteroidal anti-inflammatory drugs (NSAIDs) as a contraindication for its use.

Q: How long does the effect of one dose of Synax typically last?

A: According to the clinical pharmacology data, the effects of a single dose generally last for 8 to 12 hours.

Q: Is Synax safe to use if I drink alcohol occasionally?

A: The product label includes a specific warning stating that the risk of serious stomach bleeding is increased if a patient drinks alcohol while taking this medicine.

Q: Are there any foods or drinks that interact with Synax?

A: Official instructions advise that the medicine be taken with food or milk to help minimize potential stomach upset. Specific food or beverage interactions, other than alcohol, are generally not listed as clinically relevant in the regulatory materials.

Q: Does Synax have any known effects on kidney or liver function?

A: Yes, regulatory warnings describe the potential for serious adverse effects involving the liver (hepatotoxicity) and the kidney (renal effects). Use is generally limited or contraindicated in patients with severe kidney impairment.

Q: Can people with diabetes use Synax?

A: Regulatory warnings mention potential interactions with certain diabetes medications (like sulfonylureas). The possibility of blood sugar changes may necessitate monitoring.

Q: What is the expected timeline for treatment with Synax?

A: The timeline of use is described in regulatory documents based on the condition being addressed. This includes protocols for short-term use for acute pain and different protocols for longer-term use in chronic conditions like arthritis.

Q: Is Synax a branded drug or is a generic version available?

A: Both branded trade names and generic versions of the medicine are described in regulatory documents.

Q: What are the major contraindications for Synax use?

A: Major contraindications listed include a known allergic reaction to the drug or other NSAIDs. It is also contraindicated for use immediately before or after coronary artery bypass graft (CABG) surgery.

Q: What should I watch out for in terms of serious but rare side effects of Synax?

A: Serious but rare adverse effects described in official warnings include severe gastrointestinal bleeding or ulcers, as well as serious cardiovascular events such as heart attack and stroke.

Q: Is Synax used to treat pain?

A: Yes, regulatory documents clearly state that one of the medicine's official uses is as a pain reliever and a fever reducer.

Q: Does Synax affect blood pressure?

A: Official warnings state that medicines in this class can lead to new or worsening high blood pressure (hypertension). It may also interfere with the effectiveness of some medications used to treat high blood pressure.

Q: Is Synax generally considered safe during pregnancy (informational/descriptive only)?

A: Regulatory documents state that use is generally not recommended during the third trimester of pregnancy due to documented risk of harm to the fetus. Caution is generally advised for use during the first two trimesters as well.

Q: Has Synax been studied in children?

A: Yes, official documents describe approved uses and specific dosing for pediatric patients aged 2 years and older for the treatment of conditions such as juvenile arthritis.

Q: Is Synax included in a list of 'high-risk' medicines?

A: While the drug is not officially labeled 'high-risk,' the product does carry a Boxed Warning, which is the most serious warning required by the FDA. This warning outlines serious potential cardiovascular and gastrointestinal risks.

Q: What is the difference between the immediate-release and extended-release forms of Synax?

A: The forms differ in how quickly the active ingredient is released into the body, which affects the dosing frequency and required administration methods. For example, some forms must be swallowed whole to maintain their extended-release function.

Q: Is it common to feel tired when starting Synax?

A: Fatigue or drowsiness is listed among the potential adverse reactions associated with the medicine's central nervous system effects. This means it has been reported by users.

Q: Do other medical conditions affect how Synax is processed by the body?

A: Yes, official documents indicate that conditions like impaired liver function (hepatic impairment) or impaired kidney function (renal impairment) can affect how the body processes the drug, often requiring dosage adjustments.

Q: Are there any specific laboratory tests required while taking Synax?

A: Official documentation mentions that monitoring of blood counts, kidney function, and liver function may be recommended, particularly during long-term use.

Q: Does taking Synax affect the results of common lab tests?

A: The label notes that the drug may cause interference with the results of certain laboratory assays, such as those that measure 5-HIAA in the urine.

Q: What does the manufacturer say about the long-term safety profile of Synax?

A: The official labeling discusses specific risks associated with long-term use. These include serious gastrointestinal adverse effects, cardiovascular events, and potential kidney toxicity.

Q: Can people who are lactose intolerant take Synax?

A: The suitability for lactose-intolerant individuals depends on the inactive ingredients of the specific formulation prescribed, which are detailed in the official product documents.

Q: What is the relationship between Synax and fatigue?

A: Fatigue is listed as a potential adverse reaction associated with the medicine.

Q: Does Synax have a Black Box Warning, and what does it mean?

A: Yes, the drug carries a Boxed Warning, which is the most serious warning required by the FDA. It highlights the potential for serious cardiovascular and gastrointestinal adverse events, such as heart attack, stroke, and bleeding.

Q: What official health bodies have approved Synax?

A: The medicine has been approved for use by major governmental bodies responsible for drug regulation, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), among others.

How should Synax be stored and disposed of?

The official regulatory requirements for Synax (Naproxen Sodium Tablets) govern its storage, handling, and disposal to maintain product quality.

Storage and Handling

Synax must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, which should be tightly closed, and protected from moisture, light, and excessive heat above 40 C. To prevent accidental poisoning, the medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Synax should be disposed of using an authorized drug take-back program. Regulatory agencies generally prohibit flushing the medicine down the toilet or sink. If a take-back program is unavailable, the alternative is to mix the tablets with an undesirable substance (such as dirt or used coffee grounds) in a sealed container and discard it in the household trash, ensuring all personal information is removed from the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Synax found in:

A-Z Index: